Aurobindo Pharma is currently trading at Rs. 126.60, up by 0.20 points or 0.16% from its previous closing of Rs. 126.40 on the BSE.
The scrip opened at Rs. 126.50 and has touched a high and low of Rs. 129.20 and Rs. 124.05 respectively. So far 190465 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 199.00 on 28-Apr-2011 and a 52 week low of Rs. 80.35 on 18-Nov-2011.
Last one week high and low of the scrip stood at Rs. 141.15 and Rs. 124.05 respectively. The current market cap of the company is Rs. 3685.60 crore.
The promoters holding in the company stood at 54.76% while Institutions and Non-Institutions held 29.39% and 15.85% respectively.
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg (ANDA 091388). The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India.
Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg are the generic equivalent of Eli Lilly & Company’s Zyprexa Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Olanzapine Tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and falls under the Neurological (CNS) therapeutic category. The annual sale of Olanzapine Tablets is approximately $3.2 billion and is ready for launch.
Aurobindo now has a total of 149 ANDA approvals (121 Final approvals including 1 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |